In vivo treatment with anti-CD8 and anti-CD5 monoclonal antibodies alters induced tolerance to adjuvant arthritis
✍ Scribed by Per Larsson; Rikard Holmdahl; Lars Klareskog
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 451 KB
- Volume
- 40
- Category
- Article
- ISSN
- 0730-2312
No coin nor oath required. For personal study only.
✦ Synopsis
Resistance (low dose tolerance) to adjuvant arthritis was induced by intradermal immunization with 10 fig Mycobacterium tuberculosis administered 5 and 3 weeks before induction of arthritis. With the purpose of determining phenotypes of cells which participate in the maintenance of the induced resistance to adjuvant arthritis, tolerized rats were treated with two different anti-T-cell monoclonal antibodies. In tolerized rats, it was shown that anti-CD8 ( 0 x 8 ) antibodies, which caused an elimination of CD8+ lymphoid cells as determined by immunofluorescence analysis, made the rats responsive to an arthritogenic challenge with mycobacteria. Nine of 19 (47.4%) rats developed the disease as compared with 2 of 18 (1 1.1%) (P < 0.05) in the control antibody-treated group. Also, in vivo treatment with antLCD5 (0x19) monoclonal antibodies made the rats responsive to an arthritogenic challenge with mycobacteria. Nine of 15 (60%) anti-CD5-treated rats developed the disease as compared with 2 of 18 (1 1 .l%) (P < 0.01) rats in the control group. Immunofluorescence analysis performed after anti-CDS treatment showed a reduction of staining of CD5+ cells as well as a down-regulation of the staining intensity of CD5 cell surface receptors on the remaining CDS+ cells. These data indicate that CD8+-as well as CDS+ cells participate in the maintenance of low dose tolerance to adjuvant arthritis.